ASP lag after launch: why buy-and-bill economics can break in the first quarters

A new biologic or specialty drug administered in physician offices and hospital outpatient departments enters the Medicare Part B buy-and-bill market with a reimbursement floor based on wholesale acquisition cost (WAC), not average sales price (ASP). CMS cannot publish an ASP-based payment limit until it has at least one full quarter of manufacturer-reported sales data, and even then a two-quarter lag separates the sales period from the reimbursement period. For a drug launching mid-quarter, the WAC-based reimbursement window can stretch to nine months or more.

During that window, provider economics, manufacturer gross-to-net projections, and commercial contract structures all operate on assumptions that may not hold once ASP takes effect. This article is for commercial operations leads, market access directors, finance teams, and provider-facing account managers who need to understand why the ASP lag matters and how to model around it.

How ASP reimbursement works

The statutory formula

Under Section 1847A of the Social Security Act and implementing regulations at 42 CFR 414.904, Medicare Part B reimburses most physician-administered drugs at ASP plus 6% (reduced to approximately 4.3% after sequestration). ASP is defined as the manufacturer's weighted average of all sales to all purchasers in the United States, net of price concessions including discounts, rebates, chargebacks, and certain other adjustments.

CMS publishes ASP-based payment limits quarterly in the Medicare Part B Drug Payment Limit File. The file is organized by HCPCS code (J-codes, Q-codes) and updated every January, April, July, and October.

The two-quarter lag

CMS's ASP calculation has a built-in two-quarter lag between when sales occur and when the corresponding payment limit takes effect:

CMS confirmed this timeline in its March 2026 ASP Data Collection FAQ: "Sales data from January 1, 2026, to March 31, 2026, are received by CMS in April and used for the July 2026 payment limit file."

What happens when there is no ASP yet

For new single-source drugs and biologics where no ASP data exists, the payment limit defaults to WAC-based pricing. Under 42 CFR 414.904(e)(4), Medicare Administrative Contractors (MACs) set the payment limit at WAC + 3% (reduced from WAC + 6% effective January 1, 2019). For biosimilars entering the market after July 1, 2024, payment during the initial period is the lesser of 103% of WAC or 106% of the reference biological product's ASP.

The launch timeline: when ASP lag turns into a margin problem

A typical new biologic launch sequence

Consider a biologic that receives FDA approval in late January 2026 and launches commercially in February 2026:

If the drug launched in mid-February, the first full quarter of data would be Q2 (April–June), not Q1, because Q1 contained only partial-month sales. The first ASP would not appear until the October file, and it would be based on Q2 sales. That means the WAC + 3% window lasts from February through September: eight months.

Where the margin breaks

The margin problem occurs in three places:

1. Provider acquisition cost versus WAC reimbursement. If a provider's actual acquisition cost is at or near WAC (common for new products without deep distribution discounts), the 3% add-on provides a slim margin. For a $10,000-per-dose biologic, the margin is approximately $300 per dose. If the practice has carrying costs, waste from dose adjustments, or billing delays from NOC codes, the effective margin can turn negative.

2. ASP decline after discounts flow through. When the first ASP is published, it incorporates all price concessions: 340B ceiling price sales, GPO rebates, volume discounts, and prompt-pay discounts. If the manufacturer has offered commercial discounts or has 340B-eligible sales, the first ASP will be meaningfully below WAC. Providers who stocked inventory at near-WAC prices are then reimbursed at the new, lower ASP + 6% rate. An analysis published in AJMC documented that this lag creates a natural disincentive for providers to adopt new Part B products during the early quarters.

3. Manufacturer gross-to-net whipsaw. From the manufacturer's perspective, the first two quarters of WAC-based reimbursement may overstate actual net revenue. When ASP kicks in, the net revenue per unit may drop sharply as accumulated discounts reduce the reported ASP. Finance teams that model revenue based on WAC + 3% reimbursement may overestimate actual collections if the first ASP reflects heavy early discounting.

The 2026 regulatory changes that compound the problem

MFP inclusion in ASP

The CY 2026 Physician Fee Schedule Final Rule confirmed that units of selected drugs sold at the IRA Maximum Fair Price (MFP) must be included in the manufacturer's ASP calculation. For Part B drugs selected for Medicare negotiation (beginning with the 2028 price year), this means ASP will incorporate MFP-level transactions alongside commercial sales. Avalere Health noted that this could create a "spiraling down of the ASP" as MFP-level sales pull the average lower, particularly for drugs with a high Medicare Part B share.

CMS also stated that for quarters in which Medicare payment is based on MFP, the Part B Drug Payment Limit File will display the MFP-based payment limit (106% of MFP) rather than the ASP-based limit. CMS will suspend ASP publication for negotiated Part B drugs until generics or biosimilars reach the market.

Bona fide service fee documentation requirements

The 2026 Final Rule imposed new documentation requirements on manufacturers for bona fide service fees (BFSFs) that are excluded from the ASP calculation. Starting with the April 30, 2026 ASP submission, manufacturers must submit:

• Fair market value (FMV) summaries for all current BFSF arrangements
• Independent FMV valuations where applicable
• Certifications that BFSFs are not passed through to downstream entities

As PharmExec reported in March 2026, CMS now requires manufacturers to submit "reasonable assumptions" alongside quarterly ASP data, formalizing the role of estimation in drug pricing. This increases the compliance burden and the risk that incorrectly documented fees are included in ASP, depressing the payment limit.

Biosimilar initial pricing

For biosimilars, the CY 2026 rules set initial reimbursement at the lesser of 103% of WAC or 106% of the reference product's ASP. This means a biosimilar launching at a deep WAC discount may actually be reimbursed at the reference product's higher ASP-based rate during the initial period. Once the biosimilar's own ASP is established, however, the lower pricing flows through and reimbursement drops accordingly. This creates a temporary margin advantage for providers who adopt the biosimilar early, followed by a margin compression once ASP catches up.

Quantifying the margin impact

A worked example

Assume a new biologic with the following parameters:

• WAC: $8,000 per dose
• Acquisition cost (average): $7,800 per dose (2.5% distribution margin)
• First-year commercial rebates: 15% of WAC
• 340B share of Part B volume: 35%
• 340B ceiling price discount: approximately 40–50% below WAC (varies by product)

During the WAC period (approximately 6–9 months), provider margin per dose:

After ASP takes effect, if the first ASP reflects 340B ceiling price sales and commercial rebates:

This is the margin inversion that can break buy-and-bill economics in the first quarters after ASP takes effect. The provider purchased at one price and is reimbursed at another.

Why 340B amplifies the squeeze

Under Section 340B of the Public Health Service Act, covered entities (primarily safety-net hospitals and federally qualified health centers) purchase outpatient drugs at ceiling prices that are significantly below both WAC and commercial acquisition costs. These 340B-purchased units are included in the manufacturer's ASP calculation, pulling ASP down for all Part B providers, not just the 340B entity. The Avalere analysis of the 2026 Final Rule noted that the growing share of oncology drugs flowing through 340B channels creates a "meaningful impact on ASP" that manufacturer assumptions must now explicitly address.

For a new biologic with a high oncology indication, the 340B effect can be substantial from launch. If 35% of Part B volume goes through 340B entities in the first year, the blended ASP will be significantly below WAC even before commercial rebates are factored in.

What manufacturer teams should do before launch

Model the full ASP timeline

Finance and market access teams should model revenue at three stages:

1. WAC period (launch through first ASP publication): Revenue based on WAC + 3% reimbursement. Model provider acquisition cost, carrying cost, and margin.
2. First ASP quarter: Model the impact of 340B, commercial rebates, and prompt-pay discounts on the first ASP calculation. This is the highest-risk quarter for margin inversion.
3. Steady-state ASP: After four to six quarters of sales data, ASP stabilizes and reflects mature pricing.

Negotiate provider protection mechanisms

Some manufacturers offer provider-focused programs during the ASP transition:

• Bridge programs or administrative funds that offset the margin gap during the WAC-to-ASP transition
• Inventory management support to reduce carrying costs
• Outcome-based contracts that align reimbursement with clinical results rather than ASP swings

These mechanisms must be structured carefully to avoid being classified as inducements under the Anti-Kickback Statute or as price concessions that further depress ASP.

Account for the IRA Part B inflation rebate

The Inflation Reduction Act requires manufacturers to pay Medicare a rebate if the price of a Part B drug increases faster than the rate of inflation (measured by the Consumer Price Index for All Urban Consumers, CPI-U). This rebate is calculated quarterly and applies from the drug's first quarter on the market. For a new biologic launching at a WAC that is later reduced via ASP, the inflation rebate baseline is established at the WAC price. If WAC increases in subsequent quarters, the rebate obligation kicks in even though ASP may still be below WAC.

Track commercial contract timing relative to ASP

Commercial contracts with GPOs, IDNs, and individual health systems often include rebate or discount provisions that take effect at different times. If a large commercial rebate activates in Q2 but ASP for Q2 is not published until Q4, providers are caught in a gap where their acquisition cost reflects the rebate but reimbursement does not. Market access teams should align commercial contract effective dates with the ASP publication cycle where possible.

Prepare providers for the transition

Provider-facing account managers should communicate:

• The expected timeline for WAC-to-ASP transition
• The likely direction of ASP (up or down from WAC) based on the product's discount and 340B profile
• Billing and coding guidance for the interim period (NOC codes, JW/JZ modifiers)
• Any manufacturer-supported programs to bridge the margin gap

Key regulatory sources

Sources

• CMS, ASP Pricing Files. https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files.
• CMS, ASP Data Collection FAQs, March 2026. https://www.cms.gov/files/document/frequently-asked-questions-faqs-asp-data-collection.pdf.
• 42 CFR 414.904, "Average sales price as the basis for payment." https://www.law.cornell.edu/cfr/text/42/414.904.
• CMS, CY 2026 Medicare Physician Fee Schedule Final Rule. https://www.federalregister.gov/documents/2025/11/05/2025-19787.
• Avalere Health, "2026 MPFS Rule: Part B MFPs Included in ASP, but Questions Remain." https://advisory.avalerehealth.com/insights/2026-mpfs-rule-part-b-mfps-included-in-asp-but-questions-remain.
• AJMC, "Observations Regarding the Average Sales Price Reimbursement Methodology." https://www.ajmc.com/view/observations-regarding-the-average-sales-price-reimbursement-methodology.
• MedPAC, "Medicare Part B Drug Payment Policy Issues," June 2017. https://www.medpac.gov/wp-content/uploads/import_data/scrape_files/docs/default-source/reports/jun17_ch2.pdf.
• PharmExec, "Why CMS Is Tightening ASP Reporting and What Manufacturers Must Get Right," March 2026. https://www.pharmexec.com/view/cms-asp-reporting-manufacturers.
• Sidley Austin, "Major Changes to U.S. Government Pricing Requirements Finalized," October 2025. https://www.sidley.com/en/insights/newsupdates/2025/10/major-changes-to-us-government-pricing-requirements-finalized-with-some-wins-for-pharma-and-biotech.
• Reed Smith, "CMS Proposes Changes to Average Sales Price Calculations for Part B Drug Reimbursement." https://www.reedsmith.com/our-insights/blogs/health-industry-washington-watch/102lu2w/cms-proposes-changes-to-average-sales-price-calculations-for-part-b-drug-reimbursement.
• ISPOR, "Medicare Price Negotiation of Part B Drugs." https://www.ispor.org/docs/default-source/cti-meeting-21021-documents/551b3f08-6535-43fb-8952-113d585c3fc1.pdf.
• PMC, "Reforming Drug Price Regulation: Using Tools That Work." https://pmc.ncbi.nlm.nih.gov/articles/PMC12078953.
• HRSA, 340B Drug Pricing Program. https://www.hrsa.gov/opa.
• Elevate Health Technologies, "2026 Specialty Drug Pricing: What Infusion Practices Need to Know." https://www.elevateht.com/blog/2026-specialty-drug-pricing-what-infusion-practices-need-to-know-before-january-1st.